Clinical Trial Update: Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating LE-DT for metastatic castration-resistant prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• LE-DT

Snippet

Sponsor: INSYS Therapeutics Inc | Conditions: Prostate Cancer | Phase 2 | Status: WITHDRAWN